About This Publication

What Reta Chemical is

Reta Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is organized as a broadsheet of record for a compound in active clinical development. Every figure is study-attributed, every claim maps to a citation in Retatrutide references, and every gap in the literature — particularly the absence of long-term safety data and the absence of any approved indication — is stated plainly rather than papered over. This is not a promotional site for the compound or for any clinical application of it.

On the domain name

The modifier 'chemical' in this site's name is editorial framing — a reference to retatrutide's status as a synthetic chemical entity (a 39-amino-acid acylated peptide) and to the compound's primary identity in the published literature as a drug candidate characterized by its molecular structure. It does not describe a chemical supplier, a vendor, a pharmacy, or any product or service offered here. No chemicals are sold, distributed, or supplied from this site. This is a literature digest.

What we cover and why

Retatrutide is one of the highest-scrutiny investigational compounds in contemporary metabolic-medicine research. Its Phase 2 trial data — up to -24.2% mean body-weight change at 48 weeks, MASLD liver-fat reduction of -82.4% at 24 weeks, HbA1c reduction of -2.02% in type 2 diabetes — represent findings with genuine public interest in the research community. At the same time, the compound is not approved, its long-term safety profile is unknown, its gray-market availability is legally contested, and its body-composition effects (including lean-mass reduction) require careful reporting.

The purpose of this publication is to provide the plain-English and technical record of what the peer-reviewed literature has actually measured — with accuracy and citation discipline, and without aspirational framing, commercial language, or implied medical guidance. Readers following the Phase 3 program will find the trial record here organized by study, filed by date, and linked to source.

Editorial policy

Every quantitative claim on this site is supported by a citation in Retatrutide references. Community-reported effects are published on the effects page under an explicit 'anecdotal, not clinical evidence' label — they are never stated as findings or recommendations. Investigational status is stated on every page that discusses efficacy data. No brand names of competitor products appear anywhere on this site. No dosing advice is given. The site is updated as new trial data enter the public record.